July 8, 2020
RFA-DA-21-019 - Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed)
National Institute on Drug Abuse (NIDA)
This Notice informs interested applicants that funding opportunity announcement RFA-DA-21-019 “Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed)” has been amended to add an additional submission date.
The FOA has been modified as follows:
Currently Reads:
Part 1. Overview Information, Key Dates
Open Date (Earliest Submission Date): June 20, 2020
Letter of Intent Due Date(s): June 20, 2020
Application Due Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
AIDS Application Due Date(s): July 20, 2020
All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Scientific Merit Review: November 2020
Advisory Council Review: January 2021
Earliest Start Date: April 2021
Expiration date: July 21, 2020
Part 2, Full Text of Announcement, Section 1 Funding Opportunity Description
Goals: The purpose of this FOA is to support generation of single cell RNA-sequencing datasets for at least one brain region relevant to persistent HIV infection and opioid, cocaine and/or methamphetamine use disorder. Applications that are not responsive to this FOA will not be reviewed. In order to be responsive to this FOA, proposed projects MUST be framed to answer one or more vexing questions about persistent HIV infection in the CNS. The major thrust of the proposed project also MUST:
Part 2, Full Text of Announcement, Section II Award information
Application types allowed New
Funds Available and Anticipated Number of Awards NIDA intends to commit $5M in FY21 to fund 1-4 applications
Section V. Application Review Information, Additional Review Criteria
Resubmission Not applicable.
Revised to Read:
Part 1. Overview Information, Key Dates
Open Date (Earliest Submission Date): June 20, 2020
Letter of Intent Due Date(s): June 20, 2020, June 20, 2021
Application Due Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
AIDS Application Due Date(s): July 20, 2020 and July 20, 2021
All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Scientific Merit Review: November, 2020, November, 2021
Advisory Council Review: January 2021, January 2022
Earliest Start Date: April 2021
Expiration Date: July 21, 2021
Part 2, Full Text of Announcement, Section 1 Funding Opportunity Description
Goals: The purpose of this FOA is to support generation of single cell RNA-sequencing datasets for at least one brain region relevant to persistent HIV infection and opioid, cocaine, methamphetamine and/or cannabis use disorder. Applications that are not responsive to this FOA will not be reviewed. In order to be responsive to this FOA, proposed projects MUST be framed to answer one or more vexing questions about persistent HIV infection in the CNS. The major thrust of the proposed project also MUST:
Part 2, Full Text of Announcement, Section II Award information
Application types allowed New, Resubmission
Funds Available and Anticipated Number of Awards NIDA intends to commit $5M in FY21 to fund 1-4 applications and $4M in FY22 to fund 1-4 applications
Section V. Application Review Information, Additional Review Criteria
Resubmissions: For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
All other aspects of this FOA remain unchanged.
John Satterlee, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-1020
Email:satterleej@nida.nih.gov